STOCK TITAN

[6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Analyzing...
Positive
  • None.
Negative
  • None.
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-39152

Quantum BioPharma Ltd.
(Translation of registrant's name into English)

1 Adelaide Street East, Suite 801
Toronto, Ontario M5C 2V9

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Quantum BioPharma Ltd.    
  (Registrant)
   
  
Date: September 18, 2025     /s/ Donal Carroll    
  Donal Carroll
  Chief Financial Officer
  


EXHIBIT INDEX

 

Exhibit Number Description
  
99.1 Press Release dated September 18, 2025

Quantum BioPharma Ltd

NASDAQ:QNTM

QNTM Rankings

QNTM Latest News

QNTM Latest SEC Filings

QNTM Stock Data

72.03M
3.40M
10.75%
30.71%
1.27%
Biotechnology
Healthcare
Link
Canada
Toronto